Ironwood Pharma quiet period ends March 14
3/9/2010
Ironwood Pharmaceuticals, which is developing a new treatment for irritable bowel syndrome and constipation, will see its quiet period end on Sunday, Mar. 14. On Feb. 2, the company raised $188 million by offering 16.7 million shares at $11.25, below the range of $14-$16. J.P. Morgan, Morgan Stanley and Credit Suisse acted as lead managers on the deal.
View IPO Profile:
IRWD
|
Film Department Holdings lowers proposed IPO deal size
3/8/2010
Film Department Holdings (The Film Department), a recently formed independent movie production company based in West Hollywood, lowered the proposed deal size for its upcoming IPO on Monday. The company now plans to raise $60 million by offering 4.6 million shares after originally expecting to raise $85 million by offering 6.5 million shares. Despite the 30% reduction in deal size, The Film Department is now valued at $150 million (up 20% from $125 million) due to an increased number of shares issued under its corporate conversion. The company also reported earnings for the year ended December 2009; it generated $40 million in revenues but recorded an operating loss of -$0.8 million. Film Department Holdings has tentatively scheduled its IPO for the week of Mar. 15.
View IPO Profile:
TFDI
|
Broadband communications access systems provider Calix Networks sets IPO terms
3/8/2010
Calix Networks, which provides broadband systems and software that enable communications service providers (CSPs) to connect to their subscribers, announced terms for its IPO on Monday. The Petaluma, CA-based company plans to raise $76 million by offering 6.3 million shares at a price range of $11-13. At the mid-point of the proposed range, Calix Networks will command a market value of $439 million. The telecommunications company, which was founded in 1999 and booked $233 million in sales over the last 12 months, plans to list on the NYSE under the symbol CALX. Goldman Sachs, Morgan Stanley and Jefferies are the lead underwriters on the deal, which is expected to price on Tuesday, Mar. 23.
View IPO Profile:
CALX
|
4 IPOs planned for the week of Mar 8
3/7/2010
The following IPOs are expected to price this week:
AVEO Pharmaceuticals, which is developing a renal cell carcinoma drug similar to blockbuster Avastin, plans to raise $98 million by offering 7 million shares at a price range of $13-$15. At the mid-point of the proposed range, AVEO Pharmaceuticals will command a market value of $387.03 million. AVEO, which was founded in 2001, booked $21 million in sales over the last 12 months. The Cambridge, MA-based company plans to list on the NASDAQ under the symbol AVEO. J.P. Morgan and Morgan Stanley are the lead underwriters on the deal.
Baltic Trading Limited, which was formed by Genco Shipping to acquire a spot market focused drybulk fleet, plans to raise $245 million by offering 16.3 million shares at a price range of $14-$16. At the mid-point of the proposed range, Baltic Trading will command a market value of $337 million. The New York, NY-based company plans to list on the NYSE under the symbol BALT. Morgan Stanley and Dahlman Rose & Co are the lead underwriters on the deal.
Crude Carriers, a newly formed shipping business focused on the crude tanker industry and managed by Capital Maritime, plans to raise $270 million by offering 13.5 million shares at a price range of $19-$21. At the mid-point of the proposed range, Crude Carriers will command a market value of $310 million. The Greece-based company plans to list on the NYSE under the symbol CRU. UBS Investment Bank, BofA Merrill Lynch and Wells Fargo Securities are the lead underwriters on the deal.
Sensata Technologies, Texas Instruments' former sensors and controls business acquired by Bain Capital, plans to raise $600 million by offering 31.6 million shares at a price range of $18-$20. At the mid-point of the proposed range, Sensata Technologies will command a market value of $3.4 billion. Sensata Technologies, which was founded in 1916, booked $1.1 billion in sales over the last 12 months. The Attleboro, MA-based company plans to list on the NYSE under the symbol ST. Morgan Stanley, Barclays Capital and Goldman Sachs are the lead underwriters on the deal.
View IPO Profile:
AVEO
BALT
CRU
|
Semiconductor solutions provider MaxLinear sets IPO terms
3/5/2010
MaxLinear, a provider of highly integrated, radio-frequency analog and mixed-signal semiconductor solutions, announced terms for its IPO on Friday. The Carlsbad, CA-based company plans to raise $65 million by offering 5.4 million shares at a price range of $11-$13. At the mid-point of the proposed range, MaxLinear will command a market value of $353 million. MaxLinear, which was founded in 2003 and booked $51 million in sales for the year ended December 2009, plans to list on the NYSE under the symbol MXL. Morgan Stanley, Deutsche Bank and UBS Investment Bank are the lead underwriters on the deal, which is expected to price on Wednesday, Mar. 24.
View IPO Profile:
MXL
|
|
|
